Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.

导出 LinkOut

翻译打印收藏纠错

第一作者： Seamus,Kent

第一单位： From the Health Economics Research Centre (S.K., A.G., B.M.) and Clinical Trial Service Unit and Epidemiological Studies Unit (R.H., J.C.H., S.P., M.J.L., R.C., J.A.), Nuffield Department of Population Health, University of Oxford, United Kingdom.

作者： Seamus,Kent ^[1] ; Richard,Haynes ^[1] ; Jemma C,Hopewell ^[1] ; Sarah,Parish ^[1] ; Alastair,Gray ^[1] ; Martin J,Landray ^[1] ; Rory,Collins ^[1] ; Jane,Armitage ^[1] ; Borislava,Mihaylova ^[2] ; HPS2-THRIVE Collaborative Group

作者单位： From the Health Economics Research Centre (S.K., A.G., B.M.) and Clinical Trial Service Unit and Epidemiological Studies Unit (R.H., J.C.H., S.P., M.J.L., R.C., J.A.), Nuffield Department of Population Health, University of Oxford, United Kingdom. ^[1] From the Health Economics Research Centre (S.K., A.G., B.M.) and Clinical Trial Service Unit and Epidemiological Studies Unit (R.H., J.C.H., S.P., M.J.L., R.C., J.A.), Nuffield Department of Population Health, University of Oxford, United Kingdom. boby.mihaylova@dph.ox.ac.uk. ^[2]

关键词 cardiovascular disease clinical trial hospital costs niacin quality of life